NOTE 10 - GOING CONCERN	12 Months Ended
Dec. 31, 2012
Going Concern Disclosure [Text Block]	NOTE 10 - GOING CONCERN The Company’s consolidated financial statements are prepared using U.S. GAAP which assumes an entity is a going concern and contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant losses from its inception through December 31, 2012, which have resulted in an accumulated deficit of $30,084,992 as of December 31, 2012. The Company has minimal cash, has a working capital deficit of approximately $3,307,973, and a total stockholder’s deficit of $3,314,099 as of December 31, 2012. The Company has relied exclusively on debt and equity financing to sustain its operations. Accordingly, there is substantial doubt about its ability to continue as a going concern. Continuation of the Company as a going concern is dependent upon obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require a substantial amount of additional funds to complete the continued development of its products, product manufacturing, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the additional funding noted below, it will most likely be forced to substantially reduce or cease operations. The Company believes that it will need approximately $1,500,000 during the next 12 months for continued research and development, marketing and related activities, as well as for general corporate purposes, including manufacturing and sales. During 2012, the Company raised a total of $1,420,793 through the sale of 16,729,278 shares of common stock at prices ranging from $0.05 to $0.165 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the initial costs of development for its hospital sterilization system. Subsequent to December 31, 2012, through the date of this report, the Company raised a total of $310,000 through the sale of 10,333,332 shares of common stock at a price of $0.03 per share. The Company believes it can raise additional funds from some of the same investors who have purchased shares from 2009 to 2012, although there is no guarantee that these investors will purchase additional shares. The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.

NOTE 10 - GOING CONCERN

12 Months Ended

Dec. 31, 2012

NOTE 10 - GOING CONCERN

The Company’s consolidated financial statements are prepared using U.S. GAAP which assumes an entity is a going concern and contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred significant losses from its inception through December 31, 2012, which have resulted in an accumulated deficit of $30,084,992 as of December 31, 2012. The Company has minimal cash, has a working capital deficit of approximately $3,307,973, and a total stockholder’s deficit of $3,314,099 as of December 31, 2012. The Company has relied exclusively on debt and equity financing to sustain its operations. Accordingly, there is substantial doubt about its ability to continue as a going concern.

Continuation of the Company as a going concern is dependent upon obtaining additional capital and ultimately, upon the Company’s attaining profitable operations. The Company will require a substantial amount of additional funds to complete the continued development of its products, product manufacturing, and to fund additional losses, until revenues are sufficient to cover the Company’s operating expenses. If the Company is unsuccessful in obtaining the additional funding noted below, it will most likely be forced to substantially reduce or cease operations.

The Company believes that it will need approximately $1,500,000 during the next 12 months for continued research and development, marketing and related activities, as well as for general corporate purposes, including manufacturing and sales.

During 2012, the Company raised a total of $1,420,793 through the sale of 16,729,278 shares of common stock at prices ranging from $0.05 to $0.165 per share, which funds have been used to keep the Company current in its public reporting obligations and to pay certain other corporate obligations including the initial costs of development for its hospital sterilization system. Subsequent to December 31, 2012, through the date of this report, the Company raised a total of $310,000 through the sale of 10,333,332 shares of common stock at a price of $0.03 per share. The Company believes it can raise additional funds from some of the same investors who have purchased shares from 2009 to 2012, although there is no guarantee that these investors will purchase additional shares.

The ability of the Company to continue as a going concern is dependent on its ability to successfully accomplish the plan described in the preceding paragraphs and eventually attain profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.